Clinical Trial Update: A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

This update reports a Phase II study of EC17, a folate-hapten conjugate, in patients with progressive metastatic renal cell carcinoma, which has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• EC17 (folate-hapten conjugate)

Snippet

Sponsor: Endocyte | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED